Adding radiotherapy to checkpoint inhibitors in lung cancer

Immune-related adverse events are not more likely to occur when patients with metastatic lung cancer receive a combination of immunotherapy with checkpoint inhibitors and thoracic radiotherapy compared with those who receive checkpoint inhibitor therapy alone, a retrospective cohort study suggests.
Medscape